Abstract
Introduction
Azan staining was performed as described previously (15) . Lung tissues were fixed in 10% 142 neutral buffered formalin and thin paraffin sections (4 μm) were made. The deparaffinized sections 143 were immersed in 5% potassium dichromate solution for 1 h and stained with azocarmine G
144
(Waldeck GmbH & Co KG Division Chroma, Münster, Germany) at room temperature overnight.
145
The sections were immersed in 12-tungsto-(VI)-phosphoric acid n-hydrate solution for 1 h and 146 stained with aniline blue-orange G (Waldeck GmbH & Co KG Division Chroma) for 15 min. The 147 images were obtained using a light microscope (BX-51). For evaluating intrapulmonary arterial 148 fibrosis, the fibrotic area to vessel area ratio (%) of three IPAs from each lung section was calculated 149 using Image J software (NIH).
151
Western blotting 152 Western blotting was done as described previously (25) . Protein lysates were obtained by 153 homogenizing tissue samples with Triton-based lysis buffer. Protein concentration was measured 154 using a bicinchoninic acid method (Pierce, Rockford, IL). Equal amount of proteins (10-15 μg) were 155 separated by SDS-PAGE (7.5%) and transferred to a nitrocellulose membrane (Pall, Ann Arbor, MI).
156
After blocked with 3% bovine serum albumin (for phosphorylation-specific antibodies) or 0.5% skim 157 milk (for others), membranes were incubated with the following primary antibodies (1:500 dilution):
158 phospho-eEF2K (Ser500), total eEF2K, NADPH oxidase (NOX)-1, and 4-hydroxy-2-nonenal (4-HNE) at 4 ℃ overnight and visualized using horseradish peroxidase-conjugated 2nd antibodies
160
(1:10,000 dilution, 45 min at room temperature) and the EZ-ECL system (Biological industries,
161
Kibbutz Beit Haemek, Israel). Equal loading of protein was ensured by measuring total actin 162 expression. The resulting bands were analyzed using CS Analyzer 3.0 software (ATTO, Tokyo, 163 Japan).
165

Gelatin zymography
166
The activity of matrix metalloproteinase (MMP)-2 in lung tissues was measured by a gelatin 167 zymography as described previously (15). Protein samples were separated by SDS-PAGE (7.5%) 168 containing 1.8 mg/ml gelatin under a non-reducing condition. After washed for 1 h in the buffer 169 containing 50 mM Tris-HCl (pH 7.4), 2.5% Triton X-100, 5 mM CaCl 2 , and 1 μM ZnCl 2 , the gels 170 were incubated in the buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM CaCl 2 , and 1 μM ZnCl 2 at 171 37 ℃ for 6 h. Then the gels were stained with 0.1% Coomassie Blue G-250 (Merck KGaA, 172 Darmstadt, Germany) for 20 min and washed with ion-exchanged water until the bands were visible. with 1 N NaOH, and the volume was adjusted with saline to achieve a concentration of 24 mg/ml.
185
ACh, NA, and SNP were dissolved in distilled water. A-484954 was suspended in 0.5% CMC.
186
Antibody sources were as followings: phospho-eEF2K (Ser500) SNP: pD 2 = 6.74±0.28, E max = 68.6±6.5%, Table 2 ). to vessel area ratio of IPAs (from 64.0±5.0 %, n = 9 to 31.4±3.0 %, n = 9, p<0.01, Fig. 2AB ).
220
A-484954 significantly inhibited it (58.8±8.0 %, n = 10, p<0.01, Fig. 2AB ). 
222
Effects of A-484954 on MCT-induced expression and activation of eEF2K in lung tissues
Effects of A-484954 on MCT-induced NOX-1 expression and ROS generation in lung tissues
230
ROS contribute to the development of MCT-induced PAH (28). We examined the effects of 
Effects of A-484954 on MCT-induced MMP-2 activation and fibrosis in lung tissues
244
Finally, we examined activity of MMP-2, a down-stream enzyme of ROS related to vascular 245 remodeling in lung tissues, and intrapulmonary arterial fibrosis. MMP-2 activity (n = 7-9, p<0.01, noted that MMP-9 activity was not changed in MCT (n = 2-3, data not shown).
PAH is characterized by a persistent increase in PA pressure, that is mainly caused by 252 increased vascular contractile reactivity and hyperplasia as well as hypertrophy (18). In this study,
253
A-484954 inhibited MCT-induced increased PA pressure (Table 1 ) and intrapulmonary arterial 254 hypertrophy (Fig. 2) , but not MCT-induced impairment of endothelium-dependent and -independent 255 relaxation ( Fig. 1) . Moreover, A-484954 inhibited MCT-induced expression of NOX-1and ROS 256 generation in lung tissues (Fig. 4) . These results suggest that eEF2K mediates vascular structural 
261
We showed that MMP-2 activity was elevated in the MCT-injected rat lung tissues, and that and activity of MMP-2 increased (11). Another study revealed that high concentration of proMMP-2 268 was detected in the urine from PAH patients (1). Moreover, expression and activity of MMP-2 were elevated in the experimental models of pulmonary hypertension (4, 6, 10). On the other hand, 270 MMP-9, an inducible gelatinase, also plays an important role in the pathogenesis of PAH similar to 271 MMP-2 (7). However, MMP-9 activity was not changed by MCT in this study (n = 2-3, data not 272 shown). A report that MMP-9 activity was not increased in PAH (6) supports our results. We suppose 273 that MMP-9 activity may vary dependent on the condition and stage of PAH. It was previously 274 reported that a specific MMPs inhibitor, batimastat prevented the development of hypoxic pulmonary 275 hypertension (8). ROS, the crucial molecule in the pathogenesis of PAH, are important for activation 276 of MMPs (19). In the present study, we showed that A-484954 significantly attenuated MCT-induced 277 pulmonary arterial fibrosis (Fig. 5BC) . Poiani et al. revealed that collagen synthesis increased in 278 pulmonary artery from hypoxia-induced pulmonary hypertensive rat (16). Accordingly, it is 279 suggested that eEF2K mediates PA hypertrophy via NOX-1/ROS/MMP-2 pathway leading to 280 fibrosis.
281
We showed that not only phosphorylation (Ser500) but also expression of eEF2K increased 282 by an MCT injection (Fig. 3) . We suppose that the increased eEF2K expression may lead to 283 increased phosphorylation of eEF2K. We previously showed that eEF2K mediates the activation of 284 ERK, Akt, and p38 in rat mesenteric arterial smooth muscle cells (24). It was also reported that these 285 signaling molecules mediate the gene expression of NOX (21). Thus, it is supposed that eEF2K may 286 mediate NOX-1 expression via the activation of ERK, Akt, and p38. Moreover, it was reported that thus propose that eEF2K may mediate MMP-2 activation via the activation of these signaling future. In addition, we did not examine the right heart function in this study. Right heart failure is the 303 major predictor for mortality in the PAH patients. If the effects of A-484954 persist for a long period 304 of time, it may improve the right heart failure. That is also our important future target.
305
In summary, the present results suggest that eEF2K may at least partly mediate PA 306 hypertrophy via NOX-1/ROS/MMP-2 pathway leading to fibrosis, which contributes to the development of PAH (Fig. 6) Table 1 Group MMP-2 activity
